New Software Infuses AI Capabilities Into Koelis’ Trinity Platform

Koelis SAS’S new software integrates artificial intelligence AI-enhanced prostate magnetic resonance imaging (MRI) features into its Trinity platform.
 
The Koelis Trinity system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the company’s prostate motion tracking software (OBT Fusion). The compact Koelis Trinity system does not require interfaces with either external ultrasound equipment or external sensors. The Trinity platform’s versatility is enabling Koelis to help shape the ongoing paradigm shift in prostate cancer care to more accurate biopsy diagnoses and more choices for less invasive treatments, company bigwigs claim.
 
Koelis’ new “Promap Contour” software has been developed in collaboration with companies innovating in computer-aided design (CAD) and AI software, among which Deephealth (a wholly owned Radnet subsidiary), Siemens Healthineers, and others in progress. The Promap Contour software enables healthcare providers to use their compatible CAD/AI solution to automatically process prostate contours and lesions on MRI that can then be seamlessly transferred to the Koelis Trinity platform for 3D MRI/US fusion procedures.
 
Using the new software, urologists and radiologists can collaborate to enhance workflow efficiencies along the prostate cancer clinical pathway. The sotware also provides access to PACS/cloud connectivity and automated prostate MRI segmentation to be readily imported into the Koelis Trinity platform. The Koelis Trinity system will use that imaging data to create a 3D patient-specific prostate map for guidance of both diagnostic and treatment procedures.
 
“Koelis is proud to enhance connectivity and add an AI dimension to its products. We strongly believe that promoting workflow efficiency with a solution like DeepHealth’s, we can facilitate the adoption of Koelis fusion biopsy as a new standard of care in the USA,” Koelis Founder/CEO Antoine Leroy, Ph.D., said. 
 
Koelis technology is currently available in 50 countries with more than 500 systems in use in the United States, Europe, and Asia. The Koelis Trinity platform has been used on 1 million patients diagnosed with prostate cancer.
 
Headquartered in Grenoble, France, Koelis has been a pioneer of MRI-US fusion image guidance technology since 2006. Featuring proprietary 3D ultrasound and prostate motion tracking software (OBT Fusion), the Koelis Trinity system facilitates more accurate biopsy diagnosis as well as enabling “focal” prostate cancer treatment alternatives to traditional “total” organ treatments such as surgical prostatectomy and radiation. The company’s commitment to minimally invasive prostate cancer treatments includes a multi-center clinical registry in Europe based on Trinity-guided microwave ablation technology. Koelis has offices in Grenoble, France; Princeton, N.J.; Saarbrücken, Germany; and Singapore to serve in more than 50 countries.